Current Environment: Production

Medical Services

Specialties

Programs & Services

Education

Undergraduate School

University of Colorado at Boulder

1993, Boulder, CO

Medical School

University of Colorado School of Medicine

1999, Denver, CO

Internship

University of Colorado School of Medicine

2000, Denver, CO

Residency

University of Colorado School of Medicine

2005, Denver, CO

Fellowship

Vanderbilt Children's Hospital

2007, Nashville, TN

Professional History

Dr. Oottamasathien, is the Director of Innovation and Technology Development in the Department of Urology at Boston Children’s Hospital and an Associate Professor of Surgery at Harvard Medical School. He is a board-certified pediatric urologist specializing in complex hypospadias surgery and general pediatric urologic conditions. Dr. Oottamasathien earned his medical degree from the University of Colorado School of Medicine and completed his urology residency at the University of Colorado at Denver and Health Sciences Center. He then completed his pediatric urology fellowship at Vanderbilt University in 2007. From 2007 to 2017, he was the Director of Pediatric Urology Basic Science Research at the University of Utah and for the past four years at Massachusetts General Hospital. His research involving models, mechanisms, and new generation therapeutics to treat bladder inflammation and pain conditions (Interstitial Cystitis/Painful Bladder Syndrome) set the foundation for obtaining both K12 and R01 grants from the NIH. Recently his work on radiation-induced proctitis was awarded another 5-year R01 grant from the NIH, in conjunction with collaborators at the University of Utah. Currently, his research efforts revolve around models and mechanisms that drive various urologic conditions and developing innovative biopolymers for therapeutics and/or drug delivery.

Media

Caregiver Profile

Meet Dr. Siam Oottamasathien

Publications

  1. Real-Time Bladder Volume Monitoring for Pediatric Patients Using a Commercially Available Wearable Ultrasound Device. Neurourol Urodyn. 2025 May 04. View Abstract

  2. Editorial Comment. J Urol. 2023 Aug; 210(2):358. View Abstract

  3. An Oligomeric Sulfated Hyaluronan and Silk-Elastinlike Polymer Combination Protects against Murine Radiation Induced Proctitis. Pharmaceutics. 2022 Jan 12; 14(1). View Abstract

  4. Silk-elastinlike copolymers enhance bioaccumulation of semisynthetic glycosaminoglycan ethers for prevention of radiation induced proctitis. J Control Release. 2021 04 10; 332:503-515. View Abstract

  5. Temperature-responsive silk-elastinlike protein polymer enhancement of intravesical drug delivery of a therapeutic glycosaminoglycan for treatment of interstitial cystitis/painful bladder syndrome. Biomaterials. 2019 10; 217:119293. View Abstract

  6. Sulfated glycosaminoglycans and low-density lipoprotein receptor contribute to Clostridium difficile toxin A entry into cells. Nat Microbiol. 2019 10; 4(10):1760-1769. View Abstract

  7. Unilateral open extravesical ureteral reimplanation with contralateral dextronomer/hyaluronic acid injection performed as an outpatient therapy. J Pediatr Urol. 2018 12; 14(6):566.e1-566.e5. View Abstract

  8. IL-33 mast cell axis is central in LL-37 induced bladder inflammation and pain in a murine interstitial cystitis model. Cytokine. 2018 10; 110:420-427. View Abstract

  9. Amniotic therapeutic biomaterials in urology: current and future applications. Transl Androl Urol. 2017 Oct; 6(5):943-950. View Abstract

  10. Bladder pain in an LL-37 interstitial cystitis and painful bladder syndrome model. Am J Clin Exp Urol. 2017; 5(2):10-17. View Abstract

  11. Combination of Extracorporeal Shockwave Lithotripsy and Ureteroscopy for Large Staghorn Calculi in a Pediatric Patient: Case Report. J Endourol Case Rep. 2017; 3(1):64-66. View Abstract

  12. Silk-elastinlike protein polymers enhance the efficacy of a therapeutic glycosaminoglycan for prophylactic treatment of radiation-induced proctitis. J Control Release. 2017 Oct 10; 263:46-56. View Abstract

  13. Childhood Cancer Risk in the Siblings and Cousins of Men with Poor Semen Quality. J Urol. 2017 03; 197(3 Pt 2):898-905. View Abstract

  14. Prevention of sinonasal inflammation by a synthetic glycosaminoglycan. Int Forum Allergy Rhinol. 2017 02; 7(2):177-184. View Abstract

  15. Topical cathelicidin (LL-37) an innate immune peptide induces acute olfactory epithelium inflammation in a mouse model. Int Forum Allergy Rhinol. 2015 Dec; 5(12):1141-50. View Abstract

  16. Urologic problems in spina bifida patients transitioning to adult care. Urology. 2014 Aug; 84(2):440-4. View Abstract

  17. Prevention of anti-microbial peptide LL-37-induced apoptosis and ATP release in the urinary bladder by a modified glycosaminoglycan. PLoS One. 2013; 8(10):e77854. View Abstract

  18. LL-37 induced cystitis and the receptor for advanced glycation end-products (RAGE) pathway. Adv Biosci Biotechnol. 2013 Aug 01; 4(8B):1-8. View Abstract

  19. Padded self-adhesive strap immobilization following newborn bladder exstrophy closure: the Utah straps. J Urol. 2013 Dec; 190(6):2216-20. View Abstract

  20. Physiological relevance of LL-37 induced bladder inflammation and mast cells. J Urol. 2013 Oct; 190(4 Suppl):1596-1602. View Abstract

  21. Pediatric urinary stone composition in the United States. J Urol. 2012 Jun; 187(6):2182-7. View Abstract

  22. A murine model of inflammatory bladder disease: cathelicidin peptide induced bladder inflammation and treatment with sulfated polysaccharides. J Urol. 2011 Oct; 186(4 Suppl):1684-92. View Abstract

  23. Metastatic Crohn's disease of the penis in a pediatric patient. Inflamm Bowel Dis. 2011 Apr; 17(4):1056. View Abstract

  24. Parameatal urethral cysts in prepubertal males. J Urol. 2011 Mar; 185(3):1042-5. View Abstract

  25. Dynamically crosslinked gold nanoparticle - hyaluronan hydrogels. Adv Mater. 2010 Nov 09; 22(42):4736-40. View Abstract

  26. Photocrosslinkable hyaluronan-gelatin hydrogels for two-step bioprinting. Tissue Eng Part A. 2010 Aug; 16(8):2675-85. View Abstract

  27. 250 consecutive unilateral extravesical ureteral reimplantations in an outpatient setting. J Urol. 2010 Jul; 184(1):311-4. View Abstract

  28. Temporal-spatial protein expression in bladder tissue derived from embryonic stem cells. J Urol. 2008 Oct; 180(4 Suppl):1784-9. View Abstract

  29. Prostate epithelial cell fate. Differentiation. 2008 Jul; 76(6):682-98. View Abstract

  30. Urothelial inhibition of transforming growth factor-beta in a bladder tissue recombination model. J Urol. 2007 Oct; 178(4 Pt 2):1643-9. View Abstract

  31. Testicular tumours in children: a single-institutional experience. BJU Int. 2007 May; 99(5):1123-6. View Abstract

  32. Directed differentiation of embryonic stem cells into bladder tissue. Dev Biol. 2007 Apr 15; 304(2):556-66. View Abstract

  33. Primary extrarenal nephroblastomatosis. Urology. 2007 Jan; 69(1):184.e3-4. View Abstract

  34. Bladder tissue formation from cultured bladder urothelium. Dev Dyn. 2006 Oct; 235(10):2795-801. View Abstract

  35. Gonadoblastoma and Turner syndrome. J Urol. 2006 May; 175(5):1858-60. View Abstract

  36. Laparoscopic Palomo varicocele ligation in children and adolescents: results of 103 cases. J Urol. 2004 Oct; 172(4 Pt 2):1749-52; discussion 1752. View Abstract

  37. Recent advances in hormonal therapy for advanced prostate cancer. Oncology (Williston Park). 2003 Aug; 17(8):1047-52; discussion 1054-8. View Abstract

  38. Should routine screening for prostate-specific antigen be recommended? Arch Intern Med. 2003 Mar 24; 163(6):661-2; discussion 666. View Abstract

Simply, it’s our kids. When I was an intern and resident in general surgery, I found myself truly loving my pediatric surgery rotations. I quickly realized that I loved to take care of the kids. Now a father of three, I’ve gained an even deeper appreciation about their health and well-being. I will continue to devote my career at BCH towards caring for our children with urologic needs.

BESbswy
BESbswy